GENINUS Company Description
GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of next generation sequencing (NGS) - based genome analysis solutions in South Korea.
It offers CancerSCAN, an NGS-based cancer genome diagnosis solution; LiquidSCAN, a liquid biopsy NGS test; and Celinus, a single-cell analysis solution for ultra-precise genome analysis.
The company also provides HealthSCAN, a genetic test service; WithMe, a service that analyzes gut bacteria characteristics related to the risk of chronic diseases; and OncoSTATION, an automated clinical genome information analysis solution.
It serves hospitals, pharmaceutical companies, and researchers. The company was incorporated in 2018 and is based in Seoul, South Korea.
| Country | South Korea |
| Founded | 2018 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 62 |
| CEO | Woongyang Park |
Contact Details
Address: KDU Tower Seoul, 05836 South Korea | |
| Phone | 82 2 6949 6570 |
| Website | kr-geninus.com |
Stock Details
| Ticker Symbol | 389030 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Woongyang Park | Chief Executive Officer |
| Ku William | Chief Financial Officer |
| Yongju Bang | Chief Operating Officer |